Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Brian Kolender

Internal Medicine West Bloomfield, MI Medical Doctor

NPI 1417931015 CMS profile 154406

5799 W Maple Rd, Suite 159, West Bloomfield, MI 48322

Open in the dashboard

General payments

$5,412

289 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Brian Kolender of West Bloomfield, MI is reported in the CMS Open Payments database as having received $5,412 across 289 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $349 18
2024 General $469 27
2023 General $973 48
2022 General $655 38
2021 General $1,143 62
2020 General $781 54
2019 General $1,042 42

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Brian Kolender
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Brian Kolender were reported at $349. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Brian Kolender Internal Medicine median Middle half National median
2019 $1,042 $159 $48–$570 $163
2020 $781 $119 $33–$402 $114
2021 $1,143 $135 $37–$521 $132
2022 $655 $141 $42–$496 $149
2023 $973 $149 $45–$519 $160
2024 $469 $154 $47–$537 $164
2025 $349 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $1,204 79 payments
  2. Amgen Inc. $1,019 57 payments
  3. Amarin Pharma Inc. $616 33 payments
  4. Lilly USA, LLC $471 26 payments
  5. AstraZeneca Pharmaceuticals LP $451 15 payments
  6. Otsuka America Pharmaceutical, Inc. $236 7 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $228 13 payments
  8. GlaxoSmithKline, LLC. $176 10 payments
  9. Novartis Pharmaceuticals Corporation $133 7 payments
  10. Pfizer Inc. $115 6 payments
  11. Other $763 36 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,371 284 payments
  2. Education $41 5 payments
Products named General payments · program years 2019–2025
  1. Repatha $855 52 payments
  2. AIMOVIG $539 37 payments
  3. Vascepa $484 28 payments
  4. FARXIGA $370 10 payments
  5. RYBELSUS $322 15 payments
  6. Saxenda $237 22 payments
  7. REXULTI $236 7 payments
  8. Ozempic $230 16 payments
  9. Tresiba $201 8 payments
  10. Wegovy $195 18 payments
  11. Other $3,028 170 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 46 drugs

Part D claims

1,703

Median for Internal Medicine: 777

Drug cost

$241,596

Median for Internal Medicine: $73,373

Branded share of claims

17.5%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Repatha Sureclick Evolocumab Brand 58 $65,635
Eliquis Apixaban Brand 31 $38,879
Ozempic Semaglutide Brand 26 $33,285
Jardiance Empagliflozin Brand 26 $24,797
Entresto Sacubitril/Valsartan Brand 14 $19,766
Trulicity Dulaglutide Brand 11 $18,903
Breo Ellipta Fluticasone/Vilanterol Brand 14 $7,649
Myrbetriq Mirabegron Brand 11 $4,865
Rosuvastatin Calcium Generic 279 $4,431
Vascepa Icosapent Ethyl Brand 12 $3,684

The 10 drugs with the highest cost, of 46 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 9 billing codes

Paid by Medicare

$17,623

Medicare's payments for the services billed

Medicare patients

55

Average age 78

Services billed

156

28 women, 27 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 69%
Arthritis 27%
Diabetes 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 14 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $54
$54 — —
Wegovy
  • Novo Nordisk Inc $49
$49 — —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $48
$48 — —
AREXVY
  • GlaxoSmithKline, LLC. $36
$36 — —
NURTEC ODT
  • PFIZER INC. $26
$26 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 14 in the dashboard with a free account

Records

289 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record